Showing results (91-100 of 113) with videos related to

Sort By:
Pageof 12
Oncotargets and Therapy|August 1, 2015
Expression of ARs in triple negative breast cancer tumors: a potential prognostic factor?Aris Giannos, Martin Filipits, Flora Zagouri, et al.
Breast Cancer Research : BCR|January 12, 2005
Imaging in situ breast carcinoma (with or without an invasive component) with technetium-99m pentavalent dimercaptosuccinic acid and technetium-99m 2-methoxy isobutyl isonitrile scintimammographyVassilios Papantoniou, Spyridon Tsiouris, Ekaterini Mainta, et al.
European Journal of Internal Medicine|May 3, 2016
Randomized clinical trial comparing ten day concomitant and sequential therapies for Helicobacter pylori eradication in a high clarithromycin resistance areaSotirios D Georgopoulos, Elias Xirouchakis, Beatrice Martinez-Gonzales, et al.
Gynecologic Oncology|March 17, 2020
Lymphocytic infiltration and Chemotherapy Response Score as prognostic markers in ovarian cancer patients treated with Neoadjuvant chemotherapyMichalis Liontos, Maria Sotiropoulou, Maria Kaparelou, et al.
Molecular Imaging|April 28, 2011
Increased breast density correlates with the proliferation-seeking radiotracer (99m)Tc(V)-DMSA uptake in florid epithelial hyperplasia and in mixed ductal carcinoma in situ with invasive ductal carcinoma but not in pure invasive ductal carcinoma or in mild epithelial hyperplasiaVassilios Papantoniou, Pipitsa Valsamaki, Evangelia Sotiropoulou, et al.
Cancer Genomics & Proteomics|April 26, 2019
Opposite Prognostic Impact of Single PTEN-loss and PIK3CA Mutations in Early High-risk Breast CancerGeorgios Lazaridis, Vassiliki Kotoula, Eleni Vrettou, et al.
Cancer Chemotherapy and Pharmacology|May 8, 2015
PAI-1 and HER2 interaction in advanced breast cancer disease: evidence for added benefit from trastuzumab in HER2-negative patientsAnna Koumarianou, Georgia Karayannopoulou, Georgia Gourgioti, et al.
Clinical Breast Cancer|September 6, 2017
Correlation of MYC Gene and Protein Status With Breast Cancer Subtypes and Outcome of Patients Treated With Anthracycline-Based Adjuvant Chemotherapy. Pooled Analysis of 2 Hellenic Cooperative Group Phase III TrialsAnna Batistatou, Vassiliki Kotoula, Mattheos Bobos, et al.
Plos One|September 30, 2016
Tumor Infiltrating Lymphocytes Affect the Outcome of Patients with Operable Triple-Negative Breast Cancer in Combination with Mutated Amino Acid ClassesVassiliki Kotoula, Sotiris Lakis, Ioannis S Vlachos, et al.
Plos One|June 9, 2012
Differential response of immunohistochemically defined breast cancer subtypes to anthracycline-based adjuvant chemotherapy with or without paclitaxelGeorge Fountzilas, Urania Dafni, Mattheos Bobos, et al.
Pageof 12